Abstract: Objective To forecast hepatic activity index and liver fibrosis staging by serum golgiprotein-73（GP73） levels in individuals with chronic hepatitis B viral carriers. Methods 150 individuals with chronic HBV carriers,150 patients with chronic hepatitis B,150 patients with hepatitis B liver cirrhosis and 50 healthy persons were recruited in this study between January 2014 and December 2016,and serum GP73 levels were detected by ELISA. Liver biopsies were performed in 150 individuals with chronic HBV carriers,and liver inflammation grading and fibrosis staging were evaluated by Metavir score. Results Serum GP73 level in patients with liver cirrhosis was （231.6±20.1） ng/ml,much higher than （46.5±7.8） ng/ml in chronic HBV carrier or （90.2±10.9） ng/ml in patients with chronic hepatitis B,and all of them were higher than（36.7±6.6） ng/ml in healthy persons （P<0.05）;the liver biopsies in individuals with HBV carrier showed that G₀~G₁ were found in 105,G₂ in 30 and G₃~G₄ in 15,and serum GP73 levels were（45.2±12.8）ng/ml,（63.8±15.0）ng/ml and（83.7±20.1）ng/ml,respectively,and S0~S1 in 98,S2 in 30 and S₃~S₄ in 22,and serum GP73 levels were（45.1±16.8）ng/ml,（67.3±16.4）ng/ml and（72.0±18.4）ng/ml,respectively,suggesting obviously increased serum GP73 levels in those with significant liver histopathologic inflammation grading and significant fibrosis staging（F=16.8,F=19.2,P<0.05）;Logistic regression analysis showed that increased serum GP73 level was an independent factor for significant hepatic inflammation （OR=1.1,95% confidence interval:1.0~1.1,P<0.05） and for significant liver fibrosis （OR=2.1,95% CI:0.8~1.2,P<0.05）. Conclusion Serum GP73 level is associated with liver inflammation grade and fibrosis stage in chronic HBV carriers,which warrants further study to determine whether or not it might be acted as an potential marker for predicting liver inflammation and fibrosis.

Key words: Chronic hepatitis B, Hepatitis B viral carrier, Liver histopathology, Golgi protein 73